查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947960

注射型HIV治療藥物市場（依產品類型、年齡層、最終用戶和通路分類），全球預測（2026-2032年）

Injectable HIV Treatment Market by Product Type, Age Group, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，注射用 HIV 藥物市場價值將達到 8.1018 億美元，到 2026 年將成長到 9.1418 億美元，到 2032 年將達到 19.8423 億美元，複合年成長率為 13.65%。

關鍵市場統計數據
基準年 2025 8.1018億美元
預計年份：2026年 9.1418億美元
預測年份 2032 1,984,230,000 美元
複合年成長率 (%) 13.65%

本文探討了注射型長效抗逆轉錄病毒療法如何重塑整個治療生態系統中的依從性、治療路徑和相關人員責任。

注射型長效愛滋病治療藥物正在重新定義愛滋病治療模式，它將治療重點從每日用藥依從性轉移到規律的臨床和居家給藥，從而提高了治療的便利性並擴大了醫療服務範圍。過去十年，抗逆轉錄病毒病毒藥物化學和給藥系統的科學進步，加上患者期望的不斷變化、監管機構對探索新型治療方案的積極態度，以及醫療系統為優先實現持久病毒抑制並減少污名化和治療負擔所做的努力，共同推動了注射劑型從概念驗證走向主流臨床治療方案，尤其是在依從性存在挑戰的患者群體中。

長效抗逆轉錄病毒物的進步以及臨床、監管和報銷實踐的演變，正在從根本上改變 HIV 治療的提供模式。

注射型抗逆轉錄病毒的出現標誌著愛滋病治療領域的一個變革性時刻，這得益於分子設計和長效製劑的技術進步，從而延長了給藥間隔。這一轉變正在改變臨床決策，因為臨床醫生和患者現在除了傳統的療效和安全性終點外，還會考慮長期的藥物動力學特徵和給藥方案。因此，治療最佳化越來越關注給藥頻率、患者意願以及在門診、專科中心和家庭醫療保健機構中注射給藥的物流。

評估2025年美國關稅調整對注射用HIV藥物供應韌性、商業合約創新和籌資策略的影響

美國貿易政策和關稅的變化可能會影響注射HIV藥物的供應鏈經濟、價格談判和分銷策略，尤其是在製造商調整其全球製造地和零件採購的情況下。近期實施的關稅調整（將於2025年生效）已經影響了進口原料、專用給藥裝置和某些包裝組件的成本結構，迫使製造商重新評估其籌資策略和生產計劃。為此，一些製造商正在加快關鍵投入品的在地採購，而另一些製造商則尋求透過其他貿易協定實現關稅協調和供應來源多元化。

詳細的細分分析揭示了產品屬性、給藥頻率、患者體驗、終端用戶能力、通路和年齡層如何決定採用路徑

細分市場分析揭示了不同產品類型、給藥方案、患者體驗、最終用戶、通路和年齡層在治療、營運和可及性方面存在差異，這些因素共同影響著藥物的採納路徑。例如，卡博特韋、卡博特韋合併利匹韋林、伊斯拉曲韋和來那卡帕韋等產品不僅作用機制和耐受性不同，製劑需求和給藥方案也存在差異，這些差異會影響臨床定位和服務提供模式。例如，藥物動力學持續時間較長的藥物需要進行特定的監測和諮詢，以應對潛在的抗藥性出現和治療方案的轉換。

區域比較分析展示了監管環境、醫療保健基礎設施和文化因素將如何影響美洲、歐洲、中東和非洲以及亞太地區的醫療技術採納。

區域特徵影響著美洲、歐洲、中東和非洲以及亞太地區的監管時間表、醫療服務模式和商業策略。每個地區在醫療結構、支付模式和流行病學模式方面都具有獨特的特徵。在美洲，成熟的臨床試驗網路、某些市場的一體化支付系統以及積極的倡導團體，共同塑造了加速臨床應用、強調治療效果和准入項目的談判策略。這種環境促進了製造商、專科診所和社區組織之間的密切合作，以應對公平性和依從性方面的挑戰。

策略產業生態系統概覽：揭示製藥創新者、服務供應商和合作模式如何攜手合作，有效實現注射型愛滋病治療藥物的商業化。

關鍵產業參與者包括跨國製藥公司、專業生物技術創新企業、契約製造組織和利基服務供應商，他們共同構成了支持注射HIV治療的生態系統。領先的長效抗逆轉錄病毒和下一代藥物研發企業專注於製劑穩定性、藥物動力學持久性和安全性，以實現門診給藥。同時，這些公司正投資與契約製造製造商和器械專家建立合作關係，以確保生產的擴充性和與各種器械給藥系統的良好相容性。

產業領袖們提出了切實可行的策略建議，旨在協調推廣注射型愛滋病療法、建立穩健的供應鏈、收集證據並確保公平取得。

行業領導者必須採取多管齊下的策略，以確保永續的臨床實踐和公平的醫療服務取得。首先，製造商應優先制定整合實施計劃，協調供應鏈準備、臨床培訓和支付方參與。儘早與醫療服務提供者和專科診所合作，共同製定給藥通訊協定和醫護人員培訓課程，可以減少實施過程中的阻力，並改善病患療效。此外，企業還應設計患者援助計劃，幫助患者按時就診，為延長給藥間隔提供後勤支持，並就治療方案轉換和潛在副作用提供清晰的諮詢。

我們採用了一種透明且嚴謹的調查方法，該方法整合了二手文獻綜述、臨床醫生和支付方訪談、供應鏈檢驗以及結果的迭代交叉檢驗。

本調查方法系統性地結合了二手資料審查、專家訪談和迭代檢驗，以確保分析的嚴謹性和對決策者的相關性。二手資料研究涵蓋了同行評審的臨床文獻、監管申報文件、公共衛生指南和產品開發資訊披露，旨在全面了解治療特徵、給藥策略和觀察到的安全性。臨床試驗註冊資訊和已發表的研究報告提供了特定人群的給藥間隔、療效終點和結局方面的證據，這些證據用於人群細分和操作指導。

總之，我們的研究結果清楚地表明，注射型抗逆轉錄病毒的臨床創新必須與系統性運作一致，才能最大限度地造福患者並實現永續的獲取。

長效注射療法代表著愛滋病治療領域的一項重要進展，它有望減輕每日服藥的負擔，減少與口服藥物相關的社會歧視，並為不同病患小組提供更多提高用藥依從性的途徑。為了實現這一目標，研發人員、醫療服務提供者、支付方和社區組織必須通力合作，設計出既能兼顧臨床獲益又能兼顧實際操作的治療模式。隨著治療體系的日趨成熟，給藥頻率、病患病史、最終使用者的能力以及配送物流因素將共同決定針對特定臨床情況的合適治療方法。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的注射型 HIV 治療市場

  • 卡博特格拉維爾
  • 卡博特韋+利匹韋林
  • 特拉比爾島
  • 莉娜·卡帕大廈

9. 依年齡層別分類的注射型 HIV 治療市場

  • 老年人
  • 成人
  • 兒童

10. 依最終用戶分類的注射型愛滋病治療市場

  • 診所
  • 家庭醫療保健
  • 醫院

11. 按分銷管道分類的注射型 HIV 治療藥物市場

  • 線上
  • 離線

第12章 注射型愛滋病治療市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 按組別分類的注射型 HIV 治療市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國注射型愛滋病治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 美國注射型愛滋病治療市場

第16章 中國注射愛滋病治療市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6AA

The Injectable HIV Treatment Market was valued at USD 810.18 million in 2025 and is projected to grow to USD 914.18 million in 2026, with a CAGR of 13.65%, reaching USD 1,984.23 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 810.18 million
Estimated Year [2026] USD 914.18 million
Forecast Year [2032] USD 1,984.23 million
CAGR (%) 13.65%

Opening perspective on how injectable long-acting antiretroviral therapies are reshaping adherence, care pathways, and stakeholder responsibilities across treatment ecosystems

Injectable long-acting therapies for HIV are redefining treatment paradigms by shifting the focus from daily adherence to periodic clinical and home-based administration, improving convenience and broadening the modalities through which care is delivered. Over the last decade, scientific advances in antiretroviral chemistry and delivery systems have converged with evolving patient expectations, regulatory willingness to consider novel regimens, and health system initiatives that prioritize durable suppression while reducing stigma and treatment burden. Collectively, these forces have moved injectable formulations from experimental proof-of-concept toward mainstream clinical consideration, especially for populations facing adherence challenges.

As these therapies progress through regulatory review and clinical adoption, stakeholders must understand the implications for care models, distribution channels, and workforce training. Clinicians increasingly evaluate long-acting options within the context of integrated care pathways that include adherence counseling, monitoring for injection-site reactions, and coordination with pharmacies and specialty clinics. Payers and policy makers are exploring reimbursement frameworks that reflect administration costs and long-term benefits, while patient advocacy groups emphasize informed choice, access equity, and clear communication about benefits and risks. Consequently, executives and medical leaders require granular insight into product attributes, dosing cadence, patient segments, and end-user workflows to make informed decisions that align clinical outcomes with operational feasibility.

As such, the landscape for injectable HIV treatments now demands strategic alignment across clinical development, regulatory planning, commercialization, and patient support. Transitioning from daily oral regimens to long-acting injectable options will not only affect clinical outcomes but also reshape supply chain logistics, workforce training programs, and the economics of HIV care delivery. This introduction sets the stage for a deeper examination of the transformative shifts, segmentation implications, regulatory and tariff influences, regional dynamics, and the strategic recommendations that follow.

How advances in sustained-release antiretrovirals and evolving clinical, regulatory, and reimbursement practices are fundamentally altering HIV treatment delivery models

The advent of injectable antiretrovirals marks a transformative moment in HIV care, underpinned by technological advances in molecular design and sustained-release formulations that enable extended dosing intervals. This shift alters clinical decision-making, because clinicians and patients now weigh long-term pharmacokinetic profiles and administration schedules alongside traditional efficacy and safety endpoints. As a result, treatment optimization increasingly accounts for dosing frequency, patient preference, and the logistics of delivering injections within outpatient clinics, specialty sites, and home healthcare settings.

Concurrently, emerging evidence and real-world experience have led to evolving regulatory guidance that accommodates novel delivery mechanisms, prompting manufacturers to invest in formulation robustness and post-marketing surveillance. In turn, payers and health systems are piloting reimbursement models that consider bundled administration fees and longer-term adherence benefits, rather than episodic drug dispensing. These developments encourage manufacturers to design comprehensive support programs that encompass clinic training, injection administration certification, and patient adherence services.

Moreover, the pharmaceutical value chain is adapting to handle cold-chain requirements, extended dosing intervals, and alternative distribution networks. Specialty clinics and hospital outpatient departments are revising appointment templates to integrate injection visits, while pharmacies are expanding clinical services to coordinate follow-up and adverse event monitoring. From a patient perspective, the prospect of one-month, two-month, or multi-month dosing windows reduces daily pill burden and associated stigma, thereby influencing care engagement and retention. Taken together, these interconnected shifts require coordinated planning across clinical, commercial, and operational functions to translate long-acting injectable promise into sustainable practice.

Assessment of how 2025 tariff adjustments in the United States have reinforced supply resilience, commercial contracting innovations, and procurement strategies for injectable HIV therapies

Trade policy and tariff changes in the United States can affect supply chain economics, pricing negotiations, and distribution strategies for injectable HIV therapies, particularly as manufacturers coordinate global manufacturing footprints and component sourcing. Recent tariff adjustments introduced in 2025 have influenced cost structures for imported raw materials, specialized delivery devices, and certain packaging components, leading manufacturers to reassess sourcing strategies and production schedules. As manufacturers respond, some have accelerated localization of key inputs, while others have sought tariff harmonization through alternative trade agreements and supplier diversification.

These adjustments have practical implications for procurement teams at hospitals, clinics, and specialty distributors that must manage inventory lead times and maintain continuity of care. In particular, extended-dosing products that require precise scheduling and cold-chain integrity demand predictable supply flows; any disruption can complicate patient appointment adherence and clinical workflows. Consequently, supply chain managers are implementing contingency plans that include secondary suppliers and more conservative inventory buffers to mitigate exposure to tariff-driven lead time variability.

In addition, tariff-driven cost pressures have prompted commercial teams to revise contracting approaches with payers and provider networks. Rather than focusing solely on list pricing, manufacturers are negotiating value-based arrangements and service-inclusive contracts that address administration costs and real-world adherence benefits. These commercial models seek to align incentives across stakeholders while protecting patient access. Overall, the 2025 tariff environment has reinforced the need for nimble supply strategies, strengthened manufacturer-provider collaboration, and proactive engagement with procurement and reimbursement stakeholders to safeguard uninterrupted patient care.

Deep-dive segmentation analysis revealing how product attributes, dosing cadences, patient experience, end-user capacity, distribution channels, and age cohorts determine adoption pathways

Segmentation analysis reveals distinct therapeutic, operational, and access implications across the product types, dosing schedules, patient experiences, end users, distribution channels, and age cohorts that shape adoption pathways. Products such as cabotegravir, cabotegravir combined with rilpivirine, islatravir, and lenacapavir differ not only in mechanism of action and tolerability profiles but also in formulation requirements and administration considerations, which in turn influence clinical positioning and service delivery models. For instance, agents with longer pharmacokinetic tails necessitate specific monitoring and counseling to manage potential resistance emergence and treatment transitions.

Dosing frequency is a pivotal variable, with one-month regimens presenting different adherence and scheduling trade-offs compared with two-month intervals and three months or more options, the latter of which includes three-month and six-month alternatives. Extended-interval dosing reduces appointment frequency and may improve persistence for some patients, but it also places a premium on ensuring appointment attendance and planned follow-up to capture rare adverse events. Therefore, operational workflows vary materially depending on cadence, influencing staffing models, clinic throughput, and home-care coordination.

Patient experience segmentation between treatment-experienced and treatment-naive individuals affects clinical decision trees, as prior exposure to antiretrovirals, resistance profiles, and patient expectations inform regimen choice. End users-comprising clinics, home healthcare services, and hospitals-each present different infrastructure and staffing capabilities for administering injections and monitoring outcomes. Distribution channel distinctions across hospitals, retail pharmacies, and specialty clinics dictate storage, dispensing responsibilities, and coordination efforts; some channels may offer integrated clinical services while others focus on logistics and counseling.

Age group considerations for adolescents, adults, and pediatric populations introduce unique clinical and psychosocial dimensions, including dosing adjustments, caregiver involvement, and consent processes. Collectively, these segmentation dimensions interact in complex ways that determine which formulations and delivery models are appropriate for specific patient cohorts and care settings. As a result, developers and health systems must craft tailored rollout strategies that reflect the interplay of product properties, dosing frequency, patient history, care setting, distribution mechanics, and age-specific needs.

Comparative regional landscape analysis illustrating how regulatory environments, healthcare infrastructure, and cultural dynamics shape adoption across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics influence regulatory timelines, care delivery models, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each of which presents distinct healthcare structures, payer models, and epidemiological patterns. In the Americas, mature clinical trial networks, consolidated payer systems in certain markets, and active advocacy groups shape rapid clinical adoption and negotiation approaches that emphasize outcomes and access programs. This environment fosters close collaboration between manufacturers, specialty clinics, and community organizations to address equity and adherence challenges.

Europe, Middle East & Africa encompasses a broad spectrum of health systems, where regulatory harmonization efforts, national reimbursement assessments, and infrastructure variability affect deployment speed and service design. In some high-resource European markets, centralized HTA and pricing review processes require robust real-world evidence and pharmacoeconomic substantiation, whereas in parts of the Middle East and Africa, infrastructure constraints and differing burden of disease necessitate tailored distribution strategies and capacity-building initiatives. Manufacturers often partner with local stakeholders to implement training programs and to adapt supply chains to regional realities.

In the Asia-Pacific region, diverse payer arrangements and growing clinical research capacity coexist with rapidly evolving public health priorities. Several markets in the region place strong emphasis on cost-effectiveness and scalable service delivery, prompting manufacturers to consider tiered access models, localized manufacturing partnerships, and targeted pilot programs in urban centers before broader rollout. Across all regions, cultural factors and stigma considerations influence patient acceptance and adherence, underscoring the importance of community engagement, culturally competent education materials, and flexible service delivery options that can include clinic-based and home healthcare settings.

Strategic industry ecosystem overview that highlights how pharmaceutical innovators, service providers, and collaboration models are aligning to commercialize injectable HIV therapies effectively

Key industry participants encompass multinational pharmaceutical companies, specialized biotech innovators, contract manufacturing organizations, and niche service providers that together form an ecosystem supporting injectable HIV therapies. Leading developers of long-acting antiretrovirals and next-generation agents are focusing on formulation stability, pharmacokinetic longevity, and safety profiles that facilitate outpatient administration. These companies are simultaneously investing in partnerships with contract manufacturers and device specialists to ensure scalable production and robust device-delivery compatibility.

In parallel, specialty clinics, hospital outpatient departments, and home healthcare providers are emerging as critical collaborators in execution, often entering into value-chain partnerships that coordinate administration, monitoring, and adherence support programs. Clinical research organizations and academic networks continue to supply evidence through pragmatic trials and post-marketing observational studies, while payers and health technology assessment bodies evaluate real-world outcomes to inform coverage policies. Additionally, smaller biotech firms play an outsized role by innovating novel mechanisms of action and delivery platforms that complement established therapies, creating licensing and collaboration opportunities for larger firms seeking diversified portfolios.

Across the ecosystem, strategic alliances and commercial models are evolving to reflect shared-risk arrangements and service-inclusive contracting. Companies are prioritizing integrated solutions that bundle drug supply with administration training, patient support, and data collection to demonstrate value. The competitive landscape therefore balances therapeutic differentiation with operational capability, and success often depends on the ability to execute seamless coordination between R&D, manufacturing, clinical operations, and commercial functions.

Actionable strategic recommendations for industry leaders to ensure coordinated launches, resilient supply chains, evidence generation, and equitable access for injectable HIV therapies

Industry leaders must adopt multifaceted strategies to translate long-acting injectable innovations into sustainable clinical practice and equitable access. First, manufacturers should prioritize integrated launch planning that synchronizes supply chain readiness, clinical training, and payer engagement. Early collaboration with providers and specialty clinics to co-develop administration protocols and workforce training curricula will reduce rollout friction and improve patient outcomes. Furthermore, companies should design patient support programs that address appointment adherence, logistics for extended-dosing windows, and clear counseling on treatment transitions and potential adverse effects.

Second, commercial teams ought to craft contracting approaches that align incentives across stakeholders. Value-based and service-inclusive contracts can help reconcile higher per-dose costs with reduced visit frequency and improved persistence. Negotiations should emphasize measurable clinical endpoints and operational metrics to support reimbursement discussions. Third, manufacturers and providers should invest in data generation initiatives focused on real-world effectiveness, safety monitoring, and health economics; these data streams will strengthen payer discussions and inform iterative improvements to care pathways.

Fourth, supply chain resilience must be a priority, with diversified sourcing, localized manufacturing where feasible, and contingency inventory strategies to mitigate tariff and logistics disruptions. Fifth, companies should pursue targeted access strategies that reflect regional infrastructure and patient population needs, including partnerships with community organizations to address stigma and facilitate retention. Finally, technology-enabled solutions such as appointment reminders, telehealth follow-ups, and electronic registries will support long-term adherence and provide analytics that guide continuous improvement. Collectively, these actions will position industry leaders to navigate the clinical, operational, and commercial complexities of injectable HIV treatment adoption.

Transparent and rigorous research methodology integrating secondary literature review, clinician and payer interviews, supply chain validation, and iterative cross-validation of findings

The research methodology relied on a structured combination of secondary evidence review, primary expert engagement, and iterative validation to ensure analytical rigor and relevance to decision-makers. Secondary research encompassed peer-reviewed clinical literature, regulatory filings, public health guidance, and product development disclosures to compile a comprehensive view of therapeutic attributes, dosing strategies, and observed safety profiles. Clinical trial registries and published study reports provided evidence on dosing intervals, efficacy endpoints, and population-specific outcomes that informed segmentation and operational implications.

Primary research included in-depth interviews with clinicians, pharmacists, supply chain managers, payer representatives, and patient advocacy stakeholders to capture practical insights on administration workflows, reimbursement considerations, and patient preferences. These interviews were designed to surface real-world challenges and successful implementation practices that often do not appear in published studies. In addition, dialogues with manufacturing and distribution experts clarified requirements for cold-chain logistics, device compatibility, and contingency planning in the face of trade-policy changes.

Analytical approaches integrated qualitative thematic analysis with comparative assessment frameworks that mapped product characteristics to care settings, dosing cadences, and patient segments. Findings were cross-validated through triangulation between secondary sources and primary interview inputs, with attention to regional variability and regulatory differences. Finally, an editorial review process ensured that conclusions were supported by cited evidence and expert input, and that recommendations were actionable for commercial, clinical, and policy stakeholders.

Concluding synthesis articulating how clinical innovation in injectable antiretrovirals must be matched by system-wide execution to maximize patient benefit and sustainable access

Injectable long-acting therapies constitute a pivotal evolution in HIV treatment that offers the potential to alleviate daily pill burden, reduce stigma associated with oral dosing, and provide alternative adherence pathways for diverse patient groups. Realizing this potential requires coordinated effort across developers, providers, payers, and community organizations to design care models that reconcile clinical benefits with operational realities. As the therapeutic landscape matures, attention to dosing cadence, patient history, end-user capabilities, and distribution logistics will determine which regimens fit specific clinical contexts.

Moreover, external factors such as trade policy adjustments, regional regulatory nuances, and infrastructure variability will continue to shape deployment timelines and commercial strategies. Consequently, stakeholders that invest early in supply chain resilience, data generation, and collaborative contracting are better positioned to sustain patient access and demonstrate value. Ultimately, the shift toward injectables is not simply a clinical development story but a systems challenge that intersects clinical practice, health economics, and patient-centered care design. Stakeholders who integrate cross-functional planning with evidence-based implementation stand to improve outcomes and expand access for people living with HIV.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Injectable HIV Treatment Market, by Product Type

  • 8.1. Cabotegravir
  • 8.2. Cabotegravir Plus Rilpivirine
  • 8.3. Islatravir
  • 8.4. Lenacapavir

9. Injectable HIV Treatment Market, by Age Group

  • 9.1. Geriatrics
  • 9.2. Adults
  • 9.3. Pediatrics

10. Injectable HIV Treatment Market, by End User

  • 10.1. Clinics
  • 10.2. Home Healthcare
  • 10.3. Hospitals

11. Injectable HIV Treatment Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Injectable HIV Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Injectable HIV Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Injectable HIV Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Injectable HIV Treatment Market

16. China Injectable HIV Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Accord Healthcare Inc.
  • 17.7. Amneal Pharmaceuticals, Inc.
  • 17.8. Aurobindo Pharma Ltd.
  • 17.9. Boehringer Ingelheim International GmbH
  • 17.10. Bristol Myers Squibb Company
  • 17.11. Cipla Ltd.
  • 17.12. Dr. Reddy's Laboratories Ltd.
  • 17.13. Genentech, Inc.
  • 17.14. Gilead Sciences, Inc.
  • 17.15. Hetero Labs Limited
  • 17.16. Johnson & Johnson
  • 17.17. Lupin Limited
  • 17.18. Merck & Co., Inc.
  • 17.19. Mylan N.V.
  • 17.20. Sun Pharmaceutical Industries Ltd.
  • 17.21. Teva Pharmaceutical Industries Ltd.
  • 17.22. Theratechnologies Inc.
  • 17.23. Viatris Inc.
  • 17.24. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INJECTABLE HIV TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INJECTABLE HIV TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR PLUS RILPIVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR PLUS RILPIVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CABOTEGRAVIR PLUS RILPIVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ISLATRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ISLATRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ISLATRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY LENACAPAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY LENACAPAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY LENACAPAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GERIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GERIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ADULTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. MIDDLE EAST INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. AFRICA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. ASEAN INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. GCC INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPEAN UNION INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. BRICS INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. G7 INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NATO INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INJECTABLE HIV TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. UNITED STATES INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. CHINA INJECTABLE HIV TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)